Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

75,239 questions in 5,342 reviews

current versions

No studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intermittent/cyclic etidronate 400 mg/day vs placebo Clinical vertebral fractures № of participants: 0 (0 RCTs) · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane	no estimate extracted	NR	No studies
Intermittent/cyclic etidronate 400 mg/day vs placebo Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane	RR 1.07 [0.72, 1.58]	NR	Low
Intermittent/cyclic etidronate 400 mg/day vs placebo Hip fractures · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane	RR 0.93 [0.17, 5.19]	NR	Very low
Antiviral prophylaxis vs placebo or no treatment CMV disease: all symptomatic CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.42 [0.34, 0.52]	19 studies · 1981 participants	High
Ganciclovir vs aciclovir Death due to CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.33 [0.07, 1.58]	6 studies · 832 participants	Moderate
Ganciclovir vs aciclovir All‐cause death · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.13 [0.82, 1.58]	8 studies · 1138 participants	Moderate
Ganciclovir vs aciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.98 [0.87, 1.1]	6 studies · 1009 participants	High
Ganciclovir vs aciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.55 [0.27, 1.13]	3 studies · 268 participants	Moderate
Ganciclovir vs aciclovir Opportunistic infections: other viral infections · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.81 [0.32, 2.01]	4 studies · 740 participants	Moderate
Ganciclovir vs aciclovir Leucopenia · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 3.28 [1.48, 7.25]	6 studies · 955 participants	Low
Ganciclovir vs aciclovir Kidney dysfunction · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.96 [0.83, 1.1]	4 studies · 661 participants	Moderate
Valaciclovir vs ganciclovir or valganciclovir CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.55 [0.17, 1.74]	4 studies · 331 participants	Low
Valaciclovir vs ganciclovir or valganciclovir All‐cause death · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.97 [0.31, 12.37]	3 studies · 273 participants	Low
Valaciclovir vs ganciclovir or valganciclovir CMV infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.31 [0.91, 1.9]	4 studies · 331 participants	Low
Antiviral prophylaxis vs placebo or no treatment Death due to CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.26 [0.08, 0.78]	7 studies · 1300 participants	Moderate
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Valaciclovir vs ganciclovir or valganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.61 [0.18, 2.02]	2 studies · 190 participants	Low
Valaciclovir vs ganciclovir or valganciclovir Leucopenia · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.74 [0.45, 1.24]	2 studies · 188 participants	Moderate
Valaciclovir vs ganciclovir or valganciclovir SCr at the end of · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	3 studies · 271 participants	Moderate
Extended vs short‐duration valganciclovir CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.2 [0.12, 0.35]	2 studies · 454 participants	Moderate
Extended vs short‐duration valganciclovir All‐cause death · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.09 [0.01, 1.7]	1 study · 319 participants	Low
Extended vs short‐duration valganciclovir CMV syndrome · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.39 [0.24, 0.64]	2 studies · 454 participants	Moderate
Extended vs short‐duration valganciclovir CMV infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.27 [0.1, 0.71]	2 studies · 454 participants	Low
Extended vs short‐duration valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.64 [0.43, 0.95]	2 studies · 454 participants	Moderate
Extended vs short‐duration valganciclovir Opportunistic infections · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.71 [0.33, 1.57]	2 studies · 456 participants	Low
Antiviral prophylaxis vs placebo or no treatment All‐cause death · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.63 [0.43, 0.92]	17 studies · 1838 participants	High
Extended vs short‐duration valganciclovir Total treatment‐related adverse effects · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.16 [0.97, 1.4]	2 studies · 456 participants	Moderate
Low vs standard dose valganciclovir All‐cause death · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.2 [0.11, 4.11]	1 study · 196 participants	Low
Low vs standard dose valganciclovir CMV infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.37 [0.11, 1.22]	2 studies · 256 participants	Low
Low vs standard dose valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.33 [0.07, 1.61]	1 study · 196 participants	Low
Low vs standard dose valganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1 [0.06, 15.76]	1 study · 196 participants	Low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.3 [0.74, 2.29]	1 study · 233 participants	Low
Maribavir vs ganciclovir All‐cause death · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.5 [0.55, 4.11]	1 study · 294 participants	Low
Maribavir vs ganciclovir CMV infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.34 [1.1, 1.65]	1 study · 233 participants	Moderate
Antiviral prophylaxis vs placebo or no treatment CMV infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.61 [0.48, 0.77]	17 studies · 1786 participants	High
Maribavir vs ganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.92 [0.53, 1.61]	1 study · 303 participants	Low
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.99 [0.79, 1.25]	1 study · 303 participants	Moderate
Antiviral prophylaxis vs placebo or no treatment Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.74 [0.47, 1.17]	10 studies · 825 participants	Moderate
Antiviral prophylaxis vs placebo or no treatment Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.9 [0.78, 1.05]	13 studies · 1420 participants	High
Antiviral prophylaxis vs placebo or no treatment Leucopenia · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.03 [0.67, 1.59]	4 studies · 1125 participants	Moderate
Antiviral prophylaxis vs placebo or no treatment Kidney dysfunction · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 1.81 [0.88, 3.73]	5 studies · 668 participants	Low
Ganciclovir vs aciclovir CMV disease · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.37 [0.23, 0.6]	7 studies · 1113 participants	High
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies